Q4 2023 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2024-02-13 · accession 0001104659-24-019703
$197.9M
Reported value
5
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $113.3M | 57.3% | 4,038,842 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $26.6M | 13.4% | 1,849,947 | Common | SOLE |
| 49705R105 | KNTEUSD | Kinnate Biopharma Inc. | $22.9M | 11.6% | 9,671,643 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals, Inc. | $18.9M | 9.56% | 875,000 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $16.2M | 8.16% | 8,325,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.